Genetics in kidney disease: How much do we want to know?

American Journal of Kidney Diseases

Volumn 39, Issue 3, 2002, Pages 637-652

  Kielstein, Rita ^a   Sass, Hans Martin ^b  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Autonomy; Autosomal dominant polycystic kidney disease (ADPKD); Ethics; Family planning; Genetic testing; Genetics; Privacy

Indexed keywords

ADULT; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; CHROMOSOME ABERRATION; CLINICAL GENETICS; DIALYSIS; FAMILY PLANNING; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MEDICAL ETHICS; PATIENT RIGHT; PRIVACY; REVIEW;

EID: 0036186296     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.32402     Document Type: Article

References (51)

1. A taq 1 polymorphism identified by 26-6 (D16S125) proximal to the locus affecting adult polycystic kidney disease (PKD1) on chromosome 16
2. Some cultural and ethical reflections on moleculargenetic risk assessment
3. Genetics: Ethical issues in kidney disease
4. Genetic testing for renal diseases: Medical and ethical considerations
5. Ethical issues and cystic kidney
6. Phenotypic variability in PKD1: The family as a starting point
7. Long-term follow-up of a family with autosomal dominant polycystic kidney disease type 3
8. Consultation with the specialist. Familial nephritis/Alport syndrome
9. Determination of genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome
10. Clinical and clinical-ethical aspects of genetic prediction: The case of hereditary kidney disorders
11. Ethical issues and genetic counselling
12. Case study on autosomal dominant polycystic kidney disease
13. Genetic testing for patients with renal disease: Procedures, pitfalls, and ethical considerations
14. Research samples from families with genetic diseases: A proposed code of conduct
15. Ethical issues in genetic screening and testing, gene therapy, and scientific conduct
16. Genetic secrets
17. Right not to know or duty to know? Prenatal screening for polycystic renal disease
18. Genotyping in clinical trials
19. Baseline blood pressure and other variables influencing survival on haemodialysis of patient without overt cardiovascular disease
20. Peptides from the PKD repeats of polycystin, the PKD1 gene product, modulate pattern formation in the developing kidney
21. The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1
22. Modification of disease progression in rats with inherited polycystic kidney disease
23. Cyst formation in ADPKD: New insights from natural and targeted mutants
24. Von Hippel-Lindau disease: An important differential diagnosis of polycystic kidney disease
25. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL) (-/-) clear cell renal carcinoma proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
26. Deutsche gesellschaft fuer humangenetik: Positions-papier
27. Value neutrality in genetic counseling: An unattained ideal
28. Making responsible decisions. An interpretive ethic for genetic decisionmaking
29. A "contract model" for genetic research and health care for individuals and families
30. Genetic therapy, disability and enhancement
31. How strictly do dialysis patients want their advance directives followed?
32. Using stories to assess values and establish medical directives
33. Developing genetic privacy legislation: The South Carolina experience
34. Discontinuing immunosuppression in a child with a renal transplant: Are there limits to withdrawing life support?
35. Leitlinien zur gestaltung der patiente-bzw probandeninformation und der einverstaendniserklaerung bei genetischen studien (inkl. Pharmakogenetik)